However, whether vaccine-induced T cells traffic into established tumors and can induce tumor clearance in combination with anti-PD-1 therapy in less immunotherapy-responsive tumor types, such as HCC, has not been established. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.